Previously reported results from KRYSTAL-12 (NCT04685135), a phase 3 trial comparing adagrasib with docetaxel in previously treated patients with KRAS G12C-mutated NSCLC, showed TRAEs in 94.0% of ...

Krystal Biotech (NASDAQ:KRYS) has been on the Compounding Healthcare “Bio Boom” speculative portfolio since the investing group’s inception due to their ability to develop cutting-edge ...